The goal of this trial is to examine the therapeutic effects of intranasally-‐administered insulin (INI) on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment (aMCI) or mild Alzheimer’s disease (AD).
|Effective start/end date||3/1/13 → 4/30/16|
- University of California, San Diego (42756369///7RF1AG041845-02)
- National Institute on Aging (42756369///7RF1AG041845-02)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.